General Psychiatry - Articles - Page 133

Small Efficacy Differences Between Atypicals in Treating Schizophrenia

April 1, 2009

Section editor, Glen Spielmans, PhD

A recent meta-analysis examined all blinded clinical trials that directly compared second-generation antipsychotics, including 76 trials with 13,558 participants.

Unclear Relationship Between SSRI Use and Gestational Hypertension

April 1, 2009

Section editor, Glen Spielmans, PhD

A recent study investigated the relationship between the use of SSRIs prior to or during pregnancy and the development of gestational hypertension and preeclampsia.

Lamictal May Have Small Benefit for Bipolar Depression

April 1, 2009

Section editor, Glen Spielmans, PhD

Researchers (not paid by the drug company) examined data from GlaxoSmithKline’s database of clinical trials for lamotrigine (Lamictal) as a treatment for bipolar depression.

Learning Objectives, Healthcare Policy and Psychiatry, TCPR, April 2009

April 1, 2009

After reading these articles, you should be able to…

Atypicals for Non-psychotic disorders

March 1, 2009

Heidi W. Ashih, MD, PhD

You may have noticed a recent torrent of FDA approvals and clinical trials for atypical antipsychotics in every disorder under the sun–except psychosis. Is this simply an effort by the sponsoring companies to get us to prescribe more antipsychotics? Or are these drugs truly effective for non-psychotic disorders? What’s the quality of the evidence?

Prescribing Atypical Antipsychotics: What are the Risks?

March 1, 2009

Michael Posternak, MD

Over the past several years, the use of antipsychotics has expanded dramatically. Aside from the traditional indication, schizophrenia, various members of this class have received FDA approval for bipolar mania, bipolar depression, major depression, and autism, and increasingly they are used off-label for anxiety, insomnia, and agitation.

Two New Meta-Analyses Compare Antidepressants

March 1, 2009

Glen Spielmans, PhD

Section editor, Glen Spielmans, PhD. Dr. Spielmans has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

Two recent meta-analyses compared second-generation antidepressants (SGADs) to each other regarding efficacy and safety.

EXPERT Q&A

The Neurobiology of Schizophrenia

March 1, 2009

Fredrik Jarskog, MD

Fredrik Jarskog, MD. Associate Professor of Clinical Psychiatry, Chief of Clinical Therapeutics Lieber Center for Schizophrenia Research and Treatment New York State Psychiatric Institute/Columbia University.

Dr. Jarskog has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Dr. Jarskog has disclosed that glycine, D-serine, D-cycloserine, and Glu2/3 receptor agonists are not FDA-approved for the treatment of schizophrenia.

Dr. Jarskog, for many years the dopamine theory of schizophrenia has been dominant in the field. What is the current status of that theory?

Learning Objectives, Antipsychotic Roundup 2009, TCPR, March 2009

March 1, 2009

After reading these articles, you should be able to…

Psychotropics and Pregnancy: An Update

February 1, 2009

Daniel Carlat, MD

On May 28, 2008, The Food and Drug Administration announced a major revision in the labeling of the pregnancy and breast-feeding risk of drugs. The current labeling system was devised in 1979 and has been criticized over the years for being confusing and for failing to incorporate the most recent data.

General Psychiatry
RSS

Small Efficacy Differences Between Atypicals in Treating Schizophrenia

Unclear Relationship Between SSRI Use and Gestational Hypertension

Lamictal May Have Small Benefit for Bipolar Depression

Learning Objectives, Healthcare Policy and Psychiatry, TCPR, April 2009

Atypicals for Non-psychotic disorders

Prescribing Atypical Antipsychotics: What are the Risks?

Two New Meta-Analyses Compare Antidepressants

The Neurobiology of Schizophrenia

Learning Objectives, Antipsychotic Roundup 2009, TCPR, March 2009

Psychotropics and Pregnancy: An Update

Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

Psychopharm Secrets: Coming Off Meds

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry RSS

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry
RSS